Viatris today announced that Corinne M. Le Goff has joined the company as Chief Commercial Officer and will become a member of the company’s Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and pharmaceutical executive with more…
Roche announced that its Elecsys pTau217 assay received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This blood test, which is being developed in collaboration with Eli Lilly and Company, will be used to help identify the…
FundaMental Pharma, a neuroscience company developing first-in-class small molecule inhibitors for the treatment of a range of neurodegenerative diseases, announced the appointment of Dr. Dirk Beher as Chief Executive Officer and Executive Board member. Dr. Beher assumes this role from…
Vertex Pharmaceuticals and Alpine Immune Sciences, a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately…
Johnson & Johnson and Shockwave Medical today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of…
3M completed the planned spin-off of its health care business, which formally launches Solventum Corporation as an independent company. Solventum is listed on the New York Stock Exchange as SOLV. “This is an important day for 3M and Solventum, and…
Nazli Sahafi has been appointed as the General Manager of Roche Diagnostics Türkiye, Head of the Türkiye, Central Asia and Caucasian Countries Management Center, as of April 1, 2024. Nazli Sahafi, who started her career as a researcher and scientist…
Roche announced the U.S. Food and Drug Administration (FDA) approval of the cobas® Malaria test for use on the cobas® 6800/8800 Systems. This approved test can aid healthcare professionals in reducing potential risks of patient infection from transfused blood products.…
AbbVie and Landos Biopharma announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, a first-in-class,…
Bristol Myers Squibb today announced that the European Commission (EC) has granted approval to Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory…